Hutchens & Kramer Investment Management Group LLC Has $831,000 Holdings in Zoetis Inc. (NYSE:ZTS)

Hutchens & Kramer Investment Management Group LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 7.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,272 shares of the company’s stock after selling 359 shares during the period. Hutchens & Kramer Investment Management Group LLC’s holdings in Zoetis were worth $831,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cabot Wealth Management Inc. grew its position in Zoetis by 0.7% during the third quarter. Cabot Wealth Management Inc. now owns 60,236 shares of the company’s stock worth $11,769,000 after buying an additional 415 shares in the last quarter. Trust Co. of Oklahoma lifted its position in shares of Zoetis by 10.5% in the 3rd quarter. Trust Co. of Oklahoma now owns 8,356 shares of the company’s stock worth $1,633,000 after acquiring an additional 796 shares during the period. NBC Securities Inc. grew its holdings in shares of Zoetis by 11.9% during the 3rd quarter. NBC Securities Inc. now owns 10,959 shares of the company’s stock worth $2,141,000 after purchasing an additional 1,162 shares in the last quarter. Creative Planning increased its position in shares of Zoetis by 8.6% during the third quarter. Creative Planning now owns 90,401 shares of the company’s stock valued at $17,663,000 after purchasing an additional 7,170 shares during the period. Finally, CX Institutional raised its stake in shares of Zoetis by 6.3% in the third quarter. CX Institutional now owns 8,142 shares of the company’s stock valued at $1,591,000 after purchasing an additional 482 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock traded down $0.26 during midday trading on Tuesday, reaching $192.39. 1,413,932 shares of the company’s stock traded hands, compared to its average volume of 2,540,237. The company has a 50-day simple moving average of $188.43 and a two-hundred day simple moving average of $176.42. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a market cap of $87.79 billion, a price-to-earnings ratio of 37.12, a PEG ratio of 2.95 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company posted $1.41 earnings per share. On average, analysts anticipate that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.90%. Zoetis’s payout ratio is 33.14%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent research reports. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research increased their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday. Stifel Nicolaus upped their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.